<article>While wind energy firm Continuum is looking to raise $300 million fresh capital, Malaysian private equity firm Creador is close to investing $17.5 million in Gujarat-based Corona Remedies.</article>

While wind energy firm Continuum is looking to raise $300 million fresh capital, Malaysian private equity firm Creador is close to investing $17.5 million in Gujarat-based Corona Remedies.
<h3>Continuum looks to raise $300m fresh capital</h3>
Singapore-based <a style="color: #000080;" href="http://dealstreetasia.com/tag/continuum">Continuum Wind Energy</a>, which has an India-centric focus, is scouting for equity investors to raise $300 million of fresh capital, said <a style="color: #000080;" href="http://economictimes.indiatimes.com/industry/banking/finance/continuum-wind-energy-looking-for-equity-investors-to-raise-300-million-in-capital/articleshow/53182599.cms">a report</a> in The Economic Times.
&#8220;We are looking to raise about $300 million equity capital and have appointed investment bank Moelis to advise us on this raise,&#8221; said Arvind Bansal, chief executive at Continuum Wind Energy, is majority owned by Morgan Stanley Infrastructure Partners with over 80 per cent stake.
The move to raise funds comes after a deal to sell stake to renewable power company <a style="color: #000080;" href="http://dealstreetasia.com/tag/sunedison">SunEdison</a>, which is now bankrupt, fell through last year.
&#8220;The capital raise may contain small portion of secondary sale of securities but is primarily a growth capital round through fresh issue of equity,&#8221; Bansal said. &#8220;This will dilute the existing shareholders but a sale of the company is not contemplated at all. Morgan Stanley&#8217;s fund still has life of another 6-7 years and they will continue to remain significant shareholders in the company after the capital raise,&#8221; he added.
<h3>Creador close to investing $17.5m in Corona Remedies</h3>
Malaysian private equity firm <a style="color: #000080;" href="http://dealstreetasia.com/tag/creador-capital">Creador Capital</a> is close to investing Rs 118 crore ($17.5 million) for acquire around 20 per cent stake in Gujarat-based drug manufacturer <a style="color: #000080;" href="http://www.coronaremedies.com/">Corona Remedies</a>, according to <a style="color: #000080;" href="http://economictimes.indiatimes.com/industry/banking/finance/creador-capital-close-to-investing-rs-118-crore-for-minority-stake-in-corona-remedies/articleshow/53182648.cms">a report</a> in The Economic Times quoting sources.
Creador, which has already invested in about eight other companies in India, would be investing in Corona through a Mauritius subsidiary, the report said.
Corona is also aggressively exploring mergers and acquisitions with smaller pharma companies, for which, it is already in talks with two companies for acquisition.
Also Read:
<a style="color: #ff0000;" href="http://www.dealstreetasia.com/stories/india-sunedison-calls-off-deal-to-acquire-singapore-based-continuum-wind-21044/">India: SunEdison calls off deal to acquire Singapore-based Continuum Wind</a>
<a style="color: #ff0000;" href="http://www.dealstreetasia.com/stories/continuum-said-to-be-in-talks-to-raise-funds-to-complete-projects-38442/">Singapore-based Continuum in talks to raise funds via asset, stake sale</a>
<a style="color: #ff0000;" href="http://www.dealstreetasia.com/stories/creador-exits-from-cholamandalam-investment-sells-remaining-stake-for-32m-45317/">India: PE firm Creador exits Cholamandalam, sells remaining stake for $32m</a>
&nbsp;
<div></div>
&nbsp;
&nbsp;
&nbsp;

Continuum is looking to raise $300 million fresh capital, while Creador is close to investing $17.5 million in Gujarat-based Corona Remedies.

India Digest: Continuum looks to raise $300m; Creador close to investing $17.5m in Corona Remedies

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

India Digest: Continuum looks to raise $300m; Creador close to investing $17.5m in Corona Remedies

Start your deal-making journey now!

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief